Sareum Holdings PLC Notice of Full Year Results (8832O)
October 07 2019 - 2:00AM
UK Regulatory
TIDMSAR
RNS Number : 8832O
Sareum Holdings PLC
07 October 2019
(AIM:SAR)
7 October 2019
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
NOTICE OF FULL YEAR 2019 RESULTS
Sareum Holdings plc (AIM: SAR), the specialised small molecule
drug development business, will announce its results for the full
year ended 30 June 2019 on Tuesday 15 October.
A conference call will take place on the same day at 10:00am.
Stephen Parker, Chairman, Tim Mitchell, Chief Executive Officer and
John Reader, Chief Scientific Officer, will present the financial
and operational results followed by a Q&A session.
Dial-in details for the conference call are:
-- UK Toll Free: 0808 109 0700
-- Standard International Access: +44 (0)20 3003 2666
The call password is Sareum.
The results presentation will be available in the Document
Centre in the Investors section of the Sareum website
(www.sareum.com/investors) from 7:00am the same day.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir / Mark Swallow / David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune disease. The Company aims to generates value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases
(SDC-1801) and cancers (SDC-1802). The Company is targeting first
human clinical trials in each indication in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary data suggest SRA737 may have broad application in
combination with other oncology and immune-oncology drugs in
genetically defined patients. SRA737 was discovered and initially
developed by scientists at The Institute of Cancer Research in
collaboration with Sareum, and with funding from Cancer Research
UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra
Oncology, in a $328.5m plus royalties licence deal, with Sareum
eligible to receive 27.5% of all payments to CPF under the
agreement.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORBUBDGCGGBGCS
(END) Dow Jones Newswires
October 07, 2019 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024